Fideuram Asset Management Ireland dac Takes $936,000 Position in Medpace Holdings, Inc. $MEDP

Fideuram Asset Management Ireland dac purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,666 shares of the company’s stock, valued at approximately $936,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Optiver Holding B.V. acquired a new stake in shares of Medpace in the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter valued at approximately $30,000. Quarry LP acquired a new position in Medpace during the third quarter valued at approximately $35,000. Finally, Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Analysts Set New Price Targets

Several brokerages have commented on MEDP. Leerink Partners lowered their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Royal Bank Of Canada lowered their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Robert W. Baird lowered their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Mizuho set a $582.00 price objective on shares of Medpace in a research report on Wednesday, February 11th. Finally, Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Price Performance

Shares of MEDP opened at $447.11 on Friday. The firm has a 50 day simple moving average of $457.47 and a two-hundred day simple moving average of $513.97. The company has a market cap of $12.77 billion, a P/E ratio of 28.10, a P/E/G ratio of 2.27 and a beta of 1.19. Medpace Holdings, Inc. has a one year low of $291.28 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period in the prior year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.